Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Osimertinib, a selective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), effectively targets the EGFR T790M mutant in non-small cell lung cancer (NSCLC). However, the newly identified EGFR C797S mutation confers resistance to osimertinib. In this study, we explored the role of pyruvate dehydrogenase kinase 1 (PDK1) in osimertinib resistance. Patients exhibiting osimertinib resistance initially displayed elevated PDK1 expression. Osimertinib-resistant cell lines with the EGFR C797S mutation were established using A549, NCI-H292, PC-9, and NCI-H1975 NSCLC cells for both in vitro and in vivo investigations. These EGFR C797S mutant cells exhibited heightened phosphorylation of EGFR, leading to the activation of downstream oncogenic pathways. The EGFR C797S mutation appeared to increase PDK1-driven glycolysis through the EGFR/AKT/HIF-1α axis. Combining osimertinib with the PDK1 inhibitor leelamine helped successfully overcome osimertinib resistance in allograft models. CRISPR-mediated PDK1 knockout effectively inhibited tumor formation in xenograft models. Our study established a clear link between the EGFR C797S mutation and elevated PDK1 expression, opening new avenues for the discovery of targeted therapies and improving our understanding of the roles of EGFR mutations in cancer progression.
Abstract
Osimertinib, a selective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), effectively targets the EGFR T790M mutant in non-small cell lung cancer (NSCLC). However, the newly identified EGFR C797S mutation confers resistance to osimertinib. In this study, we explored the role of pyruvate dehydrogenase kinase 1 (PDK1) in osimertinib resistance. Patients exhibiting osimertinib resistance initially displayed elevated PDK1 expression. Osimertinib-resistant cell lines with the EGFR C797S mutation were established using A549, NCI-H292, PC-9, and NCI-H1975 NSCLC cells for both in vitro and in vivo investigations. These EGFR C797S mutant cells exhibited heightened phosphorylation of EGFR, leading to the activation of downstream oncogenic pathways. The EGFR C797S mutation appeared to increase PDK1-driven glycolysis through the EGFR/AKT/HIF-1α axis. Combining osimertinib with the PDK1 inhibitor leelamine helped successfully overcome osimertinib resistance in allograft models. CRISPR-mediated PDK1 knockout effectively inhibited tumor formation in xenograft models. Our study established a clear link between the EGFR C797S mutation and elevated PDK1 expression, opening new avenues for the discovery of targeted therapies and improving our understanding of the roles of EGFR mutations in cancer progression.
참고문헌 (52)
- Herbst, R. S., "Review of epidermal growth factor receptor biology", Int. J. Radiat. Oncol. Biol. Phys, 59, pp.21~26 (2004)
- Ciardiello, F., "EGFR antagonists in cancer treatment", N. Engl. J. Med, 358, pp.1160~1174 (2008)
- Zhang, Y. L., "The prevalence of EGFR mutation in patients with non-small cell lung cancer : a systematic review and meta-analysis", Oncotarget, 7, pp.78985~78993 (2016)
- Sharma, S. V., "Epidermal growth factor receptor mutations in lung cancer", Nat. Rev. Cancer, 7, pp.169~181 (2007)
- Morgillo, F., "Mechanisms of resistance to EGFR-targeted drugs: lung cancer", ESMO Open, 1, pp.e000060~ (2016)
- Lynch, T. J., "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib", N. Engl. J. Med, 350, pp.2129~2139 (2004)
- Cross, D. A., "AZD9291, an irreversible EGFR TKI, overcomes T790M mediated resistance to EGFR inhibitors in lung cancer", Cancer Discov, 4, pp.1046~1061 (2014)
- Ramalingam, S. S., "Overall survival with osimertinib in untreated, EGFR mutated advanced NSCLC", N. Engl. J. Med, 382, pp.41~50 (2020)
- Thress, K. S., "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M", Nat. Med, 21, pp.560~562 (2015)
- Vander Heiden, M. G., "Understanding the War burg effect : the metabolic requirements of cell proliferation", Science, 324, pp.1029~1033 (2009)
- Apicella, M., "Increased lactate secretion by cancer cells sustains non-cell autonomous adaptive resistance to MET and EGFR targeted therapies", Cell Metab, 28, pp.848~865 (2018)
- Ganapathy-Kanniappan, S., "Tumor glycolysis as a target for cancer therapy : progress and prospects", Mol. Cancer, 12, pp.152~ (2013)
- Sradhanjali, S., "Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma : a potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions", PLoS ONE, 12, pp.e0177744~ (2017)
- Liu, T., "PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer", Oncol. Rep, 37, pp.193~200 (2017)
- Stacpoole P. W., "Therapeutic targeting of the pyruvate dehydrogenase complex", pyruvate dehydrogenase kinase (PDC, J. Natl Cancer Inst, pp.2017, 109[DOI]
- Velpula, K. K., "Combined targeting of PDK1and EGFR triggers regression of glioblastoma by reversing the Warburg effect", Cancer Res, 73, pp.7277~7289 (2013)
- Yang, Z., "Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer", Eur. J. Pharm, 838, pp.41~52 (2018)
- Xu, Q., "EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect", Onco target, 8, pp.9557~9571 (2017)
- Zhang, M., "Pyruvate dehydrogenase kinase 1 contributes to cisplatin resis tance of ovarian cancer through EGFR activation", J. Cell Physiol, 234, pp.6361~6370 (2019)
- Dyrstad, S. E., "Blocking aerobic glycolysis by targeting pyruvate dehy drogenase kinase in combination with EGFR TKI and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells", Cancers, 13, pp.941~ (2021)
- Guda, K., "An improved method for staining cell colonies in clonogenic assays", Cytotechnology, 54, pp.85~88 (2007)
- Yang, Z., "Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines", Eur. J. Pharm, 789, pp.458~467 (2016)
- Lu, X., "Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer", Cancer Manag. Res, 10, pp.1231~1241 (2018)
- Leonetti, A., "Resistance mechanisms to osimertinib in EGFR-mutated non small cell lung cancer", Br. J. Cancer, 121, pp.725~737 (2019)
- Chaib, I., "Co-activation of STAT3 and YES-associated Protein 1 (YAP1)pathway in EGFR-mutant NSCLC", J. Natl Cancer Inst, 109, pp.dxj014~ (2017)
- Korotchkina, L. G., "Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase", J. Biol. Chem, 276, pp.37223~37229 (2001)
- Sutendra, G., "Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology", Front. Oncol, 3, pp.38~ (2013)
- Wang, G., "Advances in the targeting of HIF-1α and future therapeutic strategies for glioblastoma multiforme(Review)", Oncol. Rep, 37, pp.657~670 (2017)
- Kazandjian, D., "FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer", Clin. Cancer Res, 22, pp.1307~1312 (2016)
- Khozin, S., "Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer", Clin. Cancer Res, 23, pp.2131~2135 (2017)
- Yarden, Y., "The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities", Eur. J. Cancer, 37, pp.S3~S8 (2001)
- Wang, F., "Phosphorylated EGFR expression may predict outcome of EGFR TKIs therapy for the advanced NSCLC patients with wild-type EGFR", J. Exp. Clin. Cancer Res, 31, pp.65~ (2012)
- Okabe, T., "Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification", Cancer Res, 67, pp.2046~2053 (2007)
- Harrison, P. T., "Rare epidermal growth factor receptor(EGFR)mutations in non-small cell lung cancer", Semin. Cancer Biol, 61, pp.167~179 (2020)
- Shan, Y., "Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization", Cell, 149, pp.860~870 (2012)
- Xiong, D., "Implications of disease-related mutations at protein-protein interfaces", Curr. Opin. Struct. Biol, 72, pp.219~225 (2022)
- Eck, M. J., "Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer", Biochim. Biophys. Acta, 1804, pp.559~566 (2010)
- Vikis, H., "EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity", Cancer Res, 67, pp.4665~4670 (2007)
- Morgensztern, D., "PI3K", Akt, Anticancer Drugs, pp.2005, 16[DOI]
- Liu, Q., "EGFR-TKIs resistance via EGFR-independent signaling pathways", Mol. Cancer, 17, pp.53~ (2018)
- Cully, M., "Beyond PTEN mutations : the PI3K pathway as an integrator of multiple inputs during tumorigenesis", Nat. Rev. Cancer, 6, pp.184~192 (2006)
- Zhong, H., "Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor", phosphatidylinositol 3-kinase, AKT, pp.FRAP pathway in human prostate cancer cells : implications for tumor angiogenesis and ther apeutics, Cancer Res[DOI]
- Kim, J. W., "HIF-1-mediated expression of pyruvate dehydrogenase kinase : a metabolic switch required for cellular adaptation to hypoxia", Cell Metab, 3, pp.177~185 (2006)
- Chen, S., "Hypoxia-inducible factor-1 : a critical player in the survival strategy of stressed cells", J. Cell Biochem, 117, pp.267~278 (2016)
- Jeoung, N. H., "Pyruvate dehydrogenase kinases : therapeutic targets for diabetes and cancers", Diabetes Metab. J, 39, pp.188~197 (2015)
- Fan, W., "Nanotechnology for multimodal syner gistic cancer therapy", Chem. Rev, 117, pp.13566~13638 (2017)
- Bayat Mokhtari, R., "Combination therapy in combating cancer", Oncotarget, 8, pp.38022~38043 (2017)
- Jin, L., "Hemistepsin A suppresses colorectal cancer growth through inhi biting pyruvate dehydrogenase kinase activity", Sci. Rep, 10, pp.21940~ (2020)
- Park, W., "Diversity and complexity of cell death : a historical review", Exp. Mol. Med, 55, pp.1573~1594 (2023)
- Jin, L., "Drug evaluation based on phosphomimetic PDHA1 reveals the complexity of activity-related cell death in A549 non-small cell lung cancer cells", BMB Rep, 54, pp.563~568 (2021)
- Merarchi, M., "A brief overview of the antitumoral actions of Leelamine", Biomedicines, 7, pp.53~ (2019)
- Ettinger, D. S., "Non-small cell lung cancer. Version 3.2022, NCCN Clinical Practice Guidelines in Oncology", J. Natl Compr. Canc. Netw, 20, pp.497~530 (2022)